Posted by Michael Wonder on 17 Jan 2017
CTD Holdings receives FDA fast track designation for development of Trappsol Cyclo to treat Niemann-Pick Disease Type C
17 January 2017 - CTD Holdings today announced that the U.S. FDA has granted fast track designation to Trappsol Cyclo for the treatment of systemic Niemann-Pick Disease Type C, a rare and fatal genetic disease.
Trappsol Cyclo is the company's proprietary formulation of hydroxypropyl beta cyclodextrin in development for the treatment of Niemann-Pick Disease Type C; it has previously been designated an orphan drug by the FDA and the EMA.
